BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

731 related articles for article (PubMed ID: 27779194)

  • 1. Development of Risk Prediction Model for Hepatocellular Carcinoma Progression of Indeterminate Nodules in Hepatitis B Virus-Related Cirrhotic Liver.
    Cho HJ; Kim B; Lee JD; Kang DR; Kim JK; Lee JH; Shin SJ; Lee KM; Yoo BM; Lee KJ; Kim SS; Cheong JY; Cho SW
    Am J Gastroenterol; 2017 Mar; 112(3):460-470. PubMed ID: 27779194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B.
    Shin H; Jung YW; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kim YY; Choi JY; Kim SU
    Clin Mol Hepatol; 2019 Dec; 25(4):390-399. PubMed ID: 31146508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology of HCC in Brazil: incidence and risk factors in a ten-year cohort.
    Paranaguá-Vezozzo DC; Ono SK; Alvarado-Mora MV; Farias AQ; Cunha-Silva M; França JI; Alves VA; Sherman M; Carrilho FJ
    Ann Hepatol; 2014; 13(4):386-93. PubMed ID: 24927609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
    Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
    J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis.
    Chien J; Liu J; Lee MH; Jen CL; Batrla-Utermann R; Lu SN; Wang LY; You SL; Yang HI; Chen CJ
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1971-1977. PubMed ID: 27118149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis.
    Lin CW; Lin CC; Mo LR; Chang CY; Perng DS; Hsu CC; Lo GH; Chen YS; Yen YC; Hu JT; Yu ML; Lee PH; Lin JT; Yang SS
    J Hepatol; 2013 Apr; 58(4):730-5. PubMed ID: 23220252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.
    Lee MH; Yang HI; Liu J; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; You SL; Wang LY; Chen CJ;
    Hepatology; 2013 Aug; 58(2):546-54. PubMed ID: 23504622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection.
    Yamada R; Hiramatsu N; Oze T; Morishita N; Harada N; Yakushijin T; Iio S; Doi Y; Yamada A; Kaneko A; Hagiwara H; Mita E; Oshita M; Itoh T; Fukui H; Hijioka T; Katayama K; Tamura S; Yoshihara H; Imai Y; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hamasaki T; Hayashi N; Takehara T;
    J Gastroenterol; 2015 Jul; 50(7):785-94. PubMed ID: 25384794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance.
    Kim GA; Lee HC; Kim MJ; Ha Y; Park EJ; An J; Lee D; Shim JH; Kim KM; Lim YS
    J Hepatol; 2015 May; 62(5):1092-9. PubMed ID: 25445399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Arterial Phase Enhancing Nodules on MRI of Cirrhotic Liver: Risk of Progression to Hepatocellular Carcinoma and Implications for LI-RADS Classification.
    Smereka P; Doshi AM; Lavelle LP; Shanbhogue K
    AJR Am J Roentgenol; 2020 Aug; 215(2):382-389. PubMed ID: 32432909
    [No Abstract]   [Full Text] [Related]  

  • 12. Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules.
    Mokrane FZ; Lu L; Vavasseur A; Otal P; Peron JM; Luk L; Yang H; Ammari S; Saenger Y; Rousseau H; Zhao B; Schwartz LH; Dercle L
    Eur Radiol; 2020 Jan; 30(1):558-570. PubMed ID: 31444598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.
    Jeon MY; Lee HW; Kim SU; Heo JY; Han S; Kim BK; Park JY; Kim DY; Ahn SH; Han KH
    Hepatol Int; 2017 May; 11(3):268-276. PubMed ID: 28224351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
    Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
    Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy.
    Loglio A; Iavarone M; Viganò M; Orenti A; Facchetti F; Cortinovis I; Lunghi G; Ceriotti F; Occhipinti V; Rumi M; Sangiovanni A; Colombo M; Lampertico P
    Liver Int; 2019 Oct; 39(10):1964-1974. PubMed ID: 31323159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients.
    Lin YJ; Lee MH; Yang HI; Jen CL; You SL; Wang LY; Lu SN; Liu J; Chen CJ
    PLoS One; 2013; 8(4):e61448. PubMed ID: 23613855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-fetoprotein as a tumor marker in hepatocellular carcinoma: investigations in south Indian subjects with hepatotropic virus and aflatoxin etiologies.
    Murugavel KG; Mathews S; Jayanthi V; Shankar EM; Hari R; Surendran R; Vengatesan A; Raghuram K; Rajasambandam P; Murali A; Srinivas U; Palaniswamy KR; Pugazhendhi T; Thyagarajan SP
    Int J Infect Dis; 2008 Nov; 12(6):e71-6. PubMed ID: 18658001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir.
    Chiang HH; Lee CM; Hu TH; Hung CH; Wang JH; Lu SN; Lai HC; Su WP; Lin CH; Peng CY; Chen CH
    Liver Int; 2018 Nov; 38(11):1997-2005. PubMed ID: 29797410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B.
    Wong GL; Chan HL; Wong CK; Leung C; Chan CY; Ho PP; Chung VC; Chan ZC; Tse YK; Chim AM; Lau TK; Wong VW
    J Hepatol; 2014 Feb; 60(2):339-45. PubMed ID: 24128413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural history of chronic hepatitis B REVEALed.
    Chen CJ; Yang HI
    J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.